Edwards Lifesciences (EW) traded lower as traders revisited two company-specific overhangs that have lingered into 2026: the collapse of its planned JenaValve acquisition after a federal court granted a preliminary injunction sought by the FTC, and a growing set of patent disputes around key structural-heart platforms. The combination has made the stock more headline-sensitive, and a risk-off tape can amplify selling when the market’s focus shifts from growth guidance to event risk.

The FTC said it won a court ruling that halted Edwards’ proposed acquisition of JenaValve, and Edwards subsequently said it was no longer pursuing the deal. That outcome removed a once-touted path to accelerate Edwards’ position in transcatheter aortic regurgitation, and it also highlighted a tougher antitrust posture toward innovation-driven medtech deals. While Edwards has communicated confidence in its standalone outlook, the loss of the acquisition has remained a sentiment drag because it resets expectations for how quickly the company can broaden beyond its core TAVR franchise.

On the legal front, Edwards has disclosed patent litigation risk in recent filings, including claims involving its PASCAL products, and there have been fresh court developments in other Edwards-related patent matters in March 2026. Even without an immediate operational impact, investors often discount medtech names when IP disputes could introduce injunction risk, royalty exposure, or higher legal costs—especially for systems positioned as next growth legs in mitral and tricuspid therapies.

Key catalysts now center on the legal calendar and any incremental updates on Edwards’ structural-heart pipeline execution. Investors will also watch whether management reiterates or tightens 2026 targets after its latest guidance updates, and whether further court rulings or case milestones change the probability-weighted impact of ongoing patent disputes.